Viewing nowIlyang Ibandronate Sodium 150 mg (Ibandronic Acid Sodium Hydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ilyang Pharmaceutical Co., Ltd.

MFDS item code 201205953 · Approved 2012.06.27 · Insurance code 641704410
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis experienced by postmenopausal women. Osteoporosis is a condition in which bones become weak, increasing the risk of fractures. This medication helps strengthen the bones and increase bone density to prevent fractures. With consistent treatment and management, it can help maintain healthy bones.
Take 1 tablet once a month, regularly on the same day each month, in the morning with plenty of water at least 1 hour before consuming food, beverages (other than water), other oral medications, or dietary supplements (including calcium): - Swallow this medicine with plenty of water (180-240ml) while standing or sitting upright, and do not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine; take it with plain water. - Do not chew or suck the tablet, to avoid esophageal ulcers. If a patient forgets to take a dose on the scheduled dosing day: - If 8 days or more remain until the next scheduled dose, take 1 tablet the morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the previously scheduled dosing day. - If 7 days or fewer remain until the next scheduled dose, take 1 tablet on the next scheduled dosing day, and thereafter continue taking 1 tablet each month on the previously scheduled dosing day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement calcium or vitamin D. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment and a creatinine clearance of 30mL/min or greater. Use of this medicine is not recommended in patients with a creatinine clearance below 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.
The efficacy and safety of this medicine in children 18 years of age or younger have not been studied.
This medication should not be used in certain patients. For example, patients who are allergic to this medication or its ingredients, untreated hypocalcemia patients, patients who cannot sit or stand upright for more than 60 minutes, patients with esophageal function issues causing difficulty in swallowing food, and genetically lactose-intolerant patients should not take this medication. Patients with severe renal impairment should be especially cautious when using this medication. When taking this medication, side effects such as dyspepsia, nausea, abdominal pain, diarrhea, headache, muscle pain, joint pain, and rash may occur. Some patients may rarely experience flu-like symptoms, eye inflammation, or severe allergic reactions, so caution is warranted. Before taking this medication, hypocalcemia or bone and mineral metabolism disorders should be treated, and it is important to ensure adequate intake of calcium and vitamin D. This medication can irritate the gastric mucosa, so patients with gastrointestinal disorders should be especially careful. If symptoms such as difficulty swallowing, chest pain, or heartburn occur, discontinue use immediately and consult a doctor. Bisphosphonate medications carry a risk of osteonecrosis of the jaw, so prior to dental treatment, it's advisable to thoroughly check the oral condition and avoid excessive dental work during treatment. Additionally, if pain occurs in the thigh or groin while taking this medication, consider the possibility of atypical fractures and further examination may be necessary. This medication may have reduced absorption when taken with food, milk, calcium supplements, antacids, etc., so do not consume other food or medications for at least 1 hour after taking it. It is safest for pregnant or breastfeeding women not to use this medication. In case of overdose, gastrointestinal discomfort or hypocalcemia may occur, and medical personnel should be consulted immediately. Do not induce vomiting, and ensure the patient remains upright. Keep out of reach of children, and properly dispose of any unused medications to prevent environmental contamination.
dyspepsia, nausea, abdominal pain, diarrhea, distension, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, esophagitis, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial edema, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric and midshaft femoral fractures, atypical fractures of the ilium, ocular paresthesia, myasthenia, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, and the storage temperature should be maintained between 1°C to 30°C at room temperature. This ensures the effectiveness and safety of the drug.
White to nearly white rectangular film-coated tablets
1 tablet/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ilyang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.